Skip to content

Study on different embryo transfer strategies in patients with diminished ovarian reserve: a prospective randomized clinical trial

Study on different embryo transfer strategies in patients with diminished ovarian reserve: a prospective randomized clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-16008050
Enrollment
Unknown
Registered
2016-03-03
Start date
2016-04-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility, diminished ovarian reserve

Interventions

Group A:pronuclear embryo transfer(D1 transfer), reduce culture time in vitro, pronuclear embryo transfer
Group B:cleavage embryo transfer(D3 transfer)

Sponsors

Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
36 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Infertility time>=12 months, women who have at least one of the following indications for IVF: (1) Ovulation dysfunction and failed to become pregnant from ovulation induction treatment; (2) Tubal and pelvic cavity factors; (3) Endometriosis; (4) Male factors; 2. Women who must meet at least two of following indications: (1) Female aged >= 36 years; (2) Antral follicle count of bilateral ovaries 10IU/L.

Exclusion criteria

Exclusion criteria: 1. Women height<=145cm; 2. Women or their partner with abnormal chromosome karyotype excluding chromosome polymorphism; 3. Intracytoplasmic sperm injection (ICSI); 4. Normal fertilized embryos<1; 5. Women is unsuited to transfer fresh embryos due to various reasons; 6. Women who has developed moderate to severe OHSS(Golan standard); 7. Women who abnormal uterine diseases, such as uterine malformation(single angle of uterus, mediastinum uterus, double angle of uterus, double uterus), uterine adenomyosis, submucosal uterine fibroids, intrauterine adhesions and so on; 8. Hydrosalpinx is not treated; 9. Women with medical condition that represent contraindication to assisted reproductive technology and/or pregnancy, such as poorly controlled Type I or Type II diabetes; undiagnosed liver disease or dysfunction (based on serum liver enzyme testing); renal disease or abnormal serum renal function; significant anemia; history of deep venous thrombosis, pulmonary embolus, or cerebrovascular accident; uncontrolled hypertension, known symptomatic heart disease; history of or suspected cervical carcinoma, endometrial carcinoma, or breast carcinoma; undiagnosed vaginal bleeding.

Design outcomes

Primary

MeasureTime frame
implantation rate;

Secondary

MeasureTime frame
live birth rate;

Countries

China

Contacts

Public ContactBo Zhang

Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region

cestbon269@sina.com+86 0771 5802039

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026